Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Bimatoprost/Timolol Formulation A vs Ganfort in Glaucoma or Ocular Hypertension
NCT01177098Phase 3Completed
- Sponsor
- Allergan
- Start
- Oct 2010
- Primary completion
- Feb 2012
- Modality
- Orthosteric Ligands
- Countries
- 9
01
Overview
Phase 3, randomised, single-blind trial of bimatoprost and timolol in Glaucoma and ocular hypertension (2 arms), sponsored by Allergan. Primary endpoints: Change From Baseline in Worse Eye Intraocular Pressure (IOP) at Each Hour Evaluated at Week 12, Average Eye Intraocular Pressure (IOP) at Each Hour Evaluated at Week 2 and 2 more. Started Oct 2010; status: completed.
02
Drugs
bimatoprosttimolol
03
Conditions
Glaucomaocular hypertension
Beyond the preview
Go deeper on NCT01177098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01177098.